• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
  • About Us
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Epitope-Driven TB Vaccine Development: A streamlined approach using immunoinformatics, ELISpot assays, and HLA transgenic mice

Epitope-Driven TB Vaccine Development: A streamlined approach using immunoinformatics, ELISpot assays, and HLA transgenic mice

by Adam | Oct 22, 2016

Current Molecular Medicine, Curr Mol Med. 2007 Jun;7(4):351-68.
Epitope-based vaccination against pneumonic tularemia. Vaccine. 2009

Epitope-based vaccination against pneumonic tularemia. Vaccine. 2009

by Adam | Oct 22, 2016

VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone

VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone

by Adam | Oct 22, 2016

Vaccine. 2011. Jan 10;29(3):501-11. Epub 2010 Nov 4.
HelicoVax: Epitope-based therapeutic H. pylori vaccination in a mouse model of gastric cancer

HelicoVax: Epitope-based therapeutic H. pylori vaccination in a mouse model of gastric cancer

by Adam | Oct 22, 2016

Vaccine. 2011. Mar 3;29(11):2085-91

Recent Posts

  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

  1. Homepage on Doing Well and Giving Back in December

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.